- Home
- STK vs CRVS Comparison
STK vs CRVS Comparison
Compare STK & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STK | CRVS |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 646.9M | 546.7M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | STK | CRVS |
|---|---|---|
| Price | $38.48 | $6.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $13.75 |
| AVG Volume (30 Days) | 38.2K | ★ 1.7M |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 6.60% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.95 | $2.54 |
| 52 Week High | $34.31 | $9.60 |
Technical Indicators
Market Signals| Indicator | STK | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 61.47 | 35.78 |
| Support Level | $36.75 | $6.43 |
| Resistance Level | $37.49 | $7.18 |
| Average True Range (ATR) | 0.55 | 0.45 |
| MACD | 0.21 | -0.10 |
| Stochastic Oscillator | 86.67 | 15.92 |
Price Performance
Historical ComparisonAbout STK Columbia Seligman Premium Technology Growth Fund Inc
Columbia Seligman Premium Technology Growth Fund Inc is a closed-end management investment company. Its investment objective is to seek growth of capital and current income. The fund invests in various sectors such as consumer discretionary, industrials, information technology and telecommunication services. Columbia Management Investment Advisers, LLC serves as the investment manager to the fund.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).